Trial Profile

A phase I trial to evaluate WCK 6777 [Ertapenem/Zidebactam]

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 22 Mar 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ertapenem+Zidebactam Wockhardt (Primary)
Indications Gram-negative infections
Focus Adverse reactions

Most Recent Events

22 Mar 2022 New trial record
16 Mar 2022 According to a National Institute of Allergy and Infectious Diseases media release, the NIAID will sponsor the investigational new drug (IND) application for the study, this trial is being funded in whole or in part under NAIID award number HHSN272201500005I. The trial will be conducted at NIAID's Phase I clinical trial units in the USA.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com